Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Research

Executive Summary

Joint clinical research program with Bristol-Myers Squibb Diagnostics will study the combination of Medco's Adenoscan, a drug used in conjunction with cardiac imaging, with Squibb's cardiac imaging agent Cardio Tec. Medco says the combo may be superior to the use of exercise stress in conjunction with thallium-201, providing high-quality images in less than one hour. NDAs for both products are pending at FDA. Medco, which has hired investment banker Oppenheimer & Co. to explore the sale of the company ("The Pink Sheet" April 16, T&G-9), says the arrangement does not represent a licensing of any of the firm's rights to Adenoscan, held by Lyphomed.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS017340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel